Evidence map›Paper›PMID 31303270›Full record

ArticleBiochemical and biophysical research communications2019

Fidelity of a PDX-CR model for bladder cancer.

Abdul M Mondal, Ai-Hong Ma, Guangzhao Li, Ewa Krawczyk, Ruan Yuan, Jie Lu, Richard Schlegel, Lambros Stamatakis, Keith J Kowalczyk, George K Philips and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical and biophysical research communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Bioprinted research models of urological malignancy.Exploration (Beijing, China) · 2024
    Review
  7. Review
  8. 3D Tumor Models in Urology.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Biomimetic Gland Models with Engineered Stratagems.Research (Washington, D.C.) · 2023
    Review
  11. Review
  12. Article
  13. Preclinical Models for Bladder Cancer Research.Hematology/oncology clinics of North America · 2021
    Review
  14. Review
  15. Conditional Cell Reprogramming in Modeling Digestive System Diseases.Frontiers in cell and developmental biology · 2021
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Abdul M MondalCenter for Cell Reprograming, Department of Pathology, Georgetown University Medical Center, Washington DC, USA.
Ai-Hong MaDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Washington DC, USA.
Guangzhao LiCenter for Cell Reprograming, Department of Pathology, Georgetown University Medical Center, Washington DC, USA.
Ewa KrawczykCenter for Cell Reprograming, Department of Pathology, Georgetown University Medical Center, Washington DC, USA.
Ruan YuanDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Washington DC, USA; Department of Urology, Renmin Hospital, Wuhan University, Washington DC, USA.
Jie LuCenter for Cell Reprograming, Department of Pathology, Georgetown University Medical Center, Washington DC, USA.
Richard SchlegelCenter for Cell Reprograming, Department of Pathology, Georgetown University Medical Center, Washington DC, USA.
Lambros StamatakisLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA; Department of Urology, MedStar Washington Hospital Center, Washington DC, USA.
Keith J KowalczykLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA; Department of Urology, MedStar Georgetown Hospital, Washington DC, USA.
George K PhilipsLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA; Department of Oncology, MedStar Georgetown Hospital, Washington DC, USA.
Chong-Xian PanDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Washington DC, USA; VA Northern California Health Care System, Mather, CA, USA. Electronic address: cxpan@ucdavis.edu.
Xuefeng LiuCenter for Cell Reprograming, Department of Pathology, Georgetown University Medical Center, Washington DC, USA; Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA. Electronic address: xuefeng.liu@georgetown.edu.
Georgetown University · USMedStar Washington Hospital Center · USUniversity of California, Davis · USVA Northern California Health Care System · USWuhan University · CN

Funding

University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health DisparitiesU54CA233306 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARVAJAL CARMONA, LUIS GUILLERMO, CHEN, MOON SHAO-CHUANG · 2018 to 2022
$6.8M
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)R01CA222148 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2019 to 2022
$1.9M
Targeted-and timed-releasing nanotherapeutics against leukemia stem cellsR01CA176803 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PAN, CHONG-XIAN · 2015 to 2019
$1.8M
Conditionally reprogrammed cells as a novel tool for biobankingR33CA177466 · NCI · GEORGETOWN UNIVERSITY · PI SCHLEGEL, RICHARD, WELLSTEIN, ANTON · 2013 to 2015
$1.2M
NON-CANONICAL FUNCTIONS OF HTERT IN CELL IMMORTALIZATION BY HPVR21CA180524 · NCI · GEORGETOWN UNIVERSITY · PI LIU, XUEFENG · 2013 to 2014
$366k
Development of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2014 to 2017
–
BLRD VA I01 BX001784BLRD VA I01 BX003840NCI NIH HHS R01 CA176803NCI NIH HHS R01 CA222148NCI NIH HHS R21 CA180524NCI NIH HHS R33 CA177466NCI NIH HHS U54 CA233306
6 · The paper itself

Abstract

Patient-derived xenografts (PDXs) are widely recognised as a more physiologically relevant preclinical model than standard cell lines, but are expensive and low throughput, have low engraftment rate and take a long time to develop. Our newly developed conditional reprogramming (CR) technology addresses many PDX drawbacks, but lacks many in vivo factors. Here we determined whether PDXs and CRCs of the same cancer origin maintain the biological fidelity and complement each for translational research and drug development. Four CRC lines were generated from bladder cancer PDXs. Short tandem repeat (STR) analyses revealed that CRCs and their corresponding parental PDXs shared the same STRs, suggesting common cancer origins. CRCs and their corresponding parental PDXs contained the same genetic alterations. Importantly, CRCs retained the same drug sensitivity with the corresponding downstream signalling activity as their corresponding parental PDXs. This suggests that CRCs and PDXs can complement each other, and that CRCs can be used for in vitro fast, high throughput and low cost screening while PDXs can be used for in vivo validation and study of the in vivo factors during translational research and drug development.

Indexed as

AnimalsAntineoplastic AgentsCell Culture TechniquesDisease Models, AnimalDrug DevelopmentDrug Resistance, NeoplasmHumansMiceMutationTranslational Research, BiomedicalTumor Cells, CulturedUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysAntineoplastic AgentsBladder cancerCell line modelsConditional reprogrammingDrug discoveryPatient derived xenograft

Identifiers

PMID31303270
PMCPMC6777560
OpenAlexW2957218482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.